MARKET

ANIP

ANIP

ANI Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

29.50
-0.07
-0.24%
Opening 15:28 03/03 EST
OPEN
29.56
PREV CLOSE
29.57
HIGH
29.81
LOW
29.15
VOLUME
24.74K
TURNOVER
--
52 WEEK HIGH
52.22
52 WEEK LOW
23.55
MARKET CAP
364.57M
P/E (TTM)
-14.8952
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Global Hormone Replacement Therapy Market 2020 - 2025 Research Study Provides Projections of COVID-19 Pandemic in its New Report
CDN Newswire · 21h ago
Earnings Preview: ANI Pharmaceuticals (ANIP) Q4 Earnings Expected to Decline
Zacks.com · 1d ago
Global Hormone Replacement Therapy Market 2020 Growth Statistics, New Opportunities, Competitive Outlook and COVID-19 Analysis 2025
Feb 23, 2021 (CDN Newswire via Comtex) -- Global Hormone Replacement Therapy Market 2020 by Manufacturers, Type and Application, Forecast to 2025 released by...
CDN Newswire · 02/23 17:10
Combined Hormonal Contraceptives Market Size, Historical Growth, Analysis, Opportunities and Forecast To 2026
Feb 22, 2021 (Market Insight Reports) -- Selbyville Delaware, The ‘ Combined Hormonal Contraceptives market’ research report is latest addition by Market...
Market Insight Reports · 02/22 20:21
ANI Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced that ANI's Board of Directors granted non-qualified inducement stock options to purchase an aggregate of 27,006 shares of ANI's common stock to Ori Gutwerg, ANI’s Senior Vice...
Business Wire · 02/19 21:30
Global Transdermal Drug Delivery Market Trends, Share, Industry Size, Growth 2016 to 2024
Feb 19, 2021 (AmericaNewsHour) -- Research Nester has recently announced new market demand assessment research titled "Transdermal Drug Delivery Market...
AmericaNewsHour · 02/19 09:26
8-K: ANI PHARMACEUTICALS INC
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/17 23:53
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2020...
BusinessWire - BZX · 02/16 21:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ANIP. Analyze the recent business situations of ANI Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ANIP stock price target is 38.33 with a high estimate of 45.00 and a low estimate of 30.00.
EPS
Institutional Holdings
Institutions: 261
Institutional Holdings: 8.86M
% Owned: 71.65%
Shares Outstanding: 12.36M
TypeInstitutionsShares
Increased
39
427.48K
New
31
-60.27K
Decreased
42
260.25K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.78%
Pharmaceuticals & Medical Research
-1.75%
Key Executives
Chairman/Director
Patrick Walsh
President/Chief Executive Officer/Director
Nikhil Lalwani
Chief Financial Officer/Vice President - Finance
Stephen Carey
Senior Vice President/Director of Sales
Robert Schrepfer
Senior Vice President
Ori Gutwerg
Senior Vice President
James Marken
General Manager
Davinder Singh
Other
Christopher Mutz
Independent Director
Robert Brown
Independent Director
Thomas Haughey
Independent Director
David Nash
Independent Director
Thomas Penn
Independent Director
Antonio Pera
Independent Director
Jeanne Thoma
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About ANIP
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.

Webull offers kinds of ANI Pharmaceuticals Inc stock information, including NASDAQ:ANIP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANIP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANIP stock methods without spending real money on the virtual paper trading platform.